Related Experiment Videos
Long-term remission from gout associated with fenofibrate therapy
A L Hepburn1, S A Kaye, M D Feher
1Rheumatology Section, Faculty of Medicine, Imperial College of Science, Technology and Medicine, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK. a.hepburn@ic.ac.uk
Clinical Rheumatology
|February 28, 2003
Summary
Fenofibrate, a hyperlipidemia treatment, effectively lowers serum urate levels and reduces gout attacks long-term. This study shows sustained benefits in patients with both hyperlipidemia and hyperuricemia.
Area of Science:
- Nephrology
- Rheumatology
- Pharmacology
Background:
- Fenofibrate is a known hyperlipidemia treatment.
- Short-term studies indicate fenofibrate lowers urate by enhancing renal clearance.
- Long-term effects on hyperuricemia and gout remain unreported.
Observation:
- Two patients with hyperlipidemia and hyperuricemia were treated long-term with fenofibrate.
- These patients experienced sustained reductions in serum urate and lipid levels.
- Recurrent acute gout attacks remitted during fenofibrate therapy.
Findings:
- Long-term fenofibrate therapy demonstrated sustained urate-lowering effects.
- Fenofibrate treatment led to significant lipid level reductions.
- Patients achieved remission from acute gout attacks.
Implications:
- Fenofibrate may offer a dual benefit for patients with hyperlipidemia and gout.
- Further research into fenofibrate's role in gout management is warranted.
- Understanding the mechanisms of fenofibrate's uricosuric effect is crucial.